Alto Neuroscience, Inc. (ANRO)
24.03
+0.51
(+2.17%)
USD |
NYSE |
Oct 08, 16:00
24.02
-0.01
(-0.04%)
Pre-Market: 20:00
Alto Neuroscience Debt to Equity Ratio : 0.1062 for June 30, 2026
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.1062 |
| March 31, 2026 | 0.0954 |
| December 31, 2025 | 0.1585 |
| September 30, 2025 | 0.2467 |
| June 30, 2025 | 0.2213 |
| March 31, 2025 | 0.1901 |
| December 31, 2024 | 0.1119 |
| September 30, 2024 | 0.1017 |
| Date | Value |
|---|---|
| June 30, 2024 | 0.0559 |
| March 31, 2024 | 0.0519 |
| December 31, 2023 | -2.113 |
| September 30, 2023 | |
| June 30, 2023 | |
| March 31, 2023 | |
| December 31, 2022 | -2.138 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| ANI Pharmaceuticals, Inc. | 1.022 |
| Corcept Therapeutics, Inc. | 0.0133 |
| Veru, Inc. | 0.0945 |
| Johnson & Johnson | 0.5771 |
| Eli Lilly & Co. | 1.621 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 254.07M |
| Total Liabilities (Quarterly) | 34.82M |
| Shareholders Equity (Quarterly) | 219.25M |
| Current Ratio | 14.85 |
| Net Debt Paydown Yield | 0.07% |